What Does This Rejection Mean for Obesity Drugmakers?

Pharmaceutical company VIVUS  (Nasdaq: VVUS  ) may have gained approval from the Food and Drug Administration for its weight loss drug, Qsymia, over the summer, but it just received the official rejection from the European Medicines Agency, or EMA. It became clear from preliminary information released in September that Qsymia -- which was going to be launched as Qsiva in the EU -- would be rejected by the EMA. Therefore, this news didn't come as a huge surprise to investors.

VIVUS stated that it will reapply for approval, but will this company lose a big market opportunity if it can't get its drug on the European market? Does this present an opportunity for its chief rival Arena Pharmaceuticals (Nasdaq: ARNA  )  and its obesity drug, Belviq?

In the following video, health care analyst Max Macaluso discusses the reasons for Qsymia's EMA rejection and how this can impact the obesity drug market.

Editor's note: At 0:57, the speaker meant to say that Qsymia is made up of phentermine combined with topiramate. The Fool regrets the error.

With VIVUS facing this obstacle in the EU, investors should research Arena, too. The future looks bright for Arena, but there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 20, 2012, at 6:59 PM, andybaron wrote:

    This report was glaringly inaccurate. Qsymia is NOT a combination of phentermine and fenfluramine. Fenfluramine has been banned worldwide for over a decade because it causes heart valve damage. Qsymia is a combination of phentermine and topiramate, and topiramate figured significantly in the CHMP decision because it causes an increased risk of birth defects, specifically cleft lip or palate.

  • Report this Comment On October 20, 2012, at 8:31 PM, TMFMassimo wrote:

    @andybaron

    Thank you for pointing out my error! You are absolutely correct, I meant to say phentermine and topiramte.

    Max

Add your comment.

DocumentId: 2066557, ~/Articles/ArticleHandler.aspx, 4/23/2014 1:40:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

TREND TRACKER: Get Rich When the Web Goes Dark

It's time to say "goodbye" to your Internet! One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Big money is already on the move. Don't be too late to the party – find out the 1 stock to own when the Web goes dark.


Advertisement